1,080 material Form 8-K filings that 839 companies we cover made with the SEC in May 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Unitil Corporation agreed on May 6, 2025 to acquire three water utilities from the Aquarion Water Authority for $100.0 million, including about $30.0 million of assumed debt. The company has committed debt financing of $100.0 million from The Bank of Nova Scotia, and the closing is expected in late 2025, subject to approvals from state utility commissions in Massachusetts, New Hampshire and Maine.
Purchase price is $100.0 million, including approximately $30.0 million of assumed debt, subject to adjustments.
Bank of Nova Scotia committed a $100.0 million senior unsecured delayed-draw term loan facility, maturing on the first anniversary of the closing.
Closing requires approval from the Massachusetts Department of Public Utilities, the New Hampshire Public Utilities Commission and the Maine Public Utilities Commission, and is expected in late 2025.
The Aquarion Companies serve about 12,000 customers in seven Massachusetts communities and 11,000 customers in eight New Hampshire communities.
Acadia Healthcare reported first-quarter 2025 revenue of $770.5 million, up slightly from $768.1 million a year earlier, but net income attributable to the company fell to $8.4 million, or $0.09 per diluted share, from $76.4 million, or $0.83. The company affirmed its full-year 2025 guidance, which includes $2.50 to $2.80 in adjusted earnings per diluted share.
Revenue was $770.5 million versus $768.1 million in Q1 2024, a 0.3% increase.
Net income attributable to Acadia was $8.4 million ($0.09 per diluted share), down from $76.4 million ($0.83) a year earlier.
Adjusted EBITDA was $134.2 million versus $173.9 million, and transaction, legal and other costs were $31.1 million, including $31.0 million of government investigation costs.
Full-year 2025 guidance was affirmed, including revenue of $3.3 to $3.4 billion and adjusted EBITDA of $675 to $725 million.
Topgolf Callaway Brands reported first-quarter 2025 net revenues of $1,092.3 million, down 4.5% from a year earlier, and GAAP net income of $2.1 million, or $0.01 per diluted share, versus $6.5 million a year earlier. The company kept its full-year consolidated revenue and Adjusted EBITDA guidance but lowered its Topgolf revenue outlook because of a softer consumer environment, and the guidance remains subject to the pending sale of Jack Wolfskin.
Q1 2025 net revenues were $1,092.3 million, down 4.5%; GAAP net income was $2.1 million, or $0.01 per diluted share, versus $0.04 a year earlier.
Non-GAAP diluted EPS was $0.11 versus $0.08, and Adjusted EBITDA rose 4.0% to $167.3 million.
Full-year consolidated net revenue ($4.000 billion to $4.185 billion) and Adjusted EBITDA ($415 million to $505 million) guidance was maintained, while Topgolf revenue guidance was lowered to $1.680 billion to $1.790 billion from $1.725 bil
Q2 2025 outlook calls for consolidated net revenues of $1.075 billion to $1.115 billion and Adjusted EBITDA of $139 million to $159 million.
StandardAero reported first-quarter 2025 revenue of $1.4 billion, up 16.2% from a year earlier, and net income of $62.9 million, compared with $3.2 million in the prior-year quarter. The company raised its full-year 2025 revenue and Adjusted EBITDA guidance, which now includes an estimated $15 million net impact from announced tariffs.
Revenue of $1,435.6 million, up 16.2% from $1,235.7 million; diluted EPS of $0.19 versus $0.01 a year earlier
Net income of $62.9 million, helped by $33.8 million lower interest expense than the prior-year quarter
2025 revenue guidance raised to $5.8 billion to $6.0 billion (from $5.8 billion to $6.0 billion prior range); Adjusted EBITDA guidance raised to $775 million to $795 million from $770 million to $790 million
Entegris said CEO Bertrand Loy will retire as President and Chief Executive Officer when his successor starts, anticipated on August 18, 2025. Board member David Reeder was appointed on May 11, 2025 to succeed him, and Loy will serve as Executive Chair after that date. The filing sets out Reeder's pay package, including a $1,000,000 base salary and an initial equity award with a total target grant date value of $11,100,000.
Bertrand Loy retires as President and CEO effective on Reeder's start date, anticipated August 18, 2025; he will then serve as Executive Chair.
David Reeder, a Board member since March 2024 and Chewy CFO since February 2024, was appointed on May 11, 2025.
Reeder's offer includes a $1,000,000 base salary, a 120% target bonus, a $410,000 cash sign-on bonus, and initial equity awards with a total target grant date value of $11,100,000.
Reeder's change-in-control severance equals three times base salary plus three times the greater of his highest bonus in the prior three years or target bonus.
Arrowhead Pharmaceuticals reported fiscal second-quarter 2025 results for the period ended March 31, 2025, with revenue of $542.7 million versus none a year earlier and net income attributable to the company of $370.4 million, compared with a loss of $125.3 million in the prior-year quarter. The company also said it expects to be funded into 2028 following its Sarepta Therapeutics agreement, and that its CFO, Ken Myszkowski, will retire effective May 13, 2025, succeeded by Daniel Apel.
Net income attributable to Arrowhead was $370.4 million, or $2.75 per diluted share, versus a loss of $1.02 per share a year earlier.
Research and development expenses rose to $133.1 million from $101.1 million.
CFO Ken Myszkowski retires effective May 13, 2025; Daniel Apel succeeds him.
ZoomInfo reported first quarter 2025 GAAP revenue of $305.7 million, down 1% from a year earlier, while GAAP operating income rose to $50.3 million from $43.0 million and diluted EPS was $0.08 versus $0.04. The company raised the low end of its full-year 2025 GAAP revenue guidance to $1.195 billion-$1.205 billion from $1.185 billion-$1.205 billion, and its adjusted EPS guidance to $0.96-$0.98 from $0.95-$0.97. Shareholders also learn that the stock will begin trading under the symbol GTM on May 13, 2025.
GAAP revenue of $305.7 million, down 1% year over year; adjusted operating income of $100.9 million, down 15%
GAAP net income of $26.8 million, or $0.08 per diluted share, versus $15.1 million, or $0.04, a year earlier
Full-year 2025 GAAP revenue guidance of $1.195 billion-$1.205 billion, with the prior range at $1.185 billion-$1.205 billion
Common stock to trade on Nasdaq as GTM before market open on May 13, 2025, replacing the ZI symbol
Maiden Holdings reported a first-quarter 2025 net loss of $8.6 million, or $0.09 per diluted share, compared with net income of $1.5 million in the first quarter of 2024. Book value per common share fell 17.4% to $0.38 at March 31, 2025, while the company said its pending Kestrel combination and sale of its International Insurance Services operation are targeted for the second quarter of 2025.
Q1 2025 net loss attributable to common shareholders was $8.6 million, or $0.09 per diluted share, versus net income of $1.5 million in Q1 2024.
Underwriting income was $7.5 million, compared with an underwriting loss of $7.5 million in Q1 2024, driven by $12.4 million of favorable prior year loss development.
Book value per common share decreased 17.4% to $0.38; adjusted book value per share decreased 6.6% to $1.42 at March 31, 2025.
Shareholders approved all Kestrel proposals on April 29, 2025; the company targets completing the Kestrel and IIS transactions in the second quarter of 2025.
RadNet reported first-quarter 2025 revenue of $471.4 million, up 9.2%, but Adjusted EBITDA fell 20.6% to $46.4 million and the company posted a net loss attributable to RadNet of $37.9 million, compared with a $2.8 million loss a year earlier. The company raised its full-year 2025 revenue and Adjusted EBITDA guidance ranges, citing the Southern California wildfires and severe winter weather that it said reduced first-quarter revenue by about $22 million.
Total Company revenue rose to $471.4 million from $431.7 million; Adjusted EBITDA fell to $46.4 million from $58.5 million.
Net loss per share was $(0.51) versus $(0.04) a year earlier; adjusted diluted loss per share was $(0.35) versus adjusted earnings of $0.07.
Imaging Center revenue guidance was raised to $1,835 million to $1,885 million from $1,825 million to $1,875 million; Adjusted EBITDA guidance was raised to $268 million to $276 million from $265 million to $273 million.
RadNet signed a definitive agreement on April 15, 2025 to acquire iCAD, Inc., subject to customary closing conditions.
BWX Technologies announced that Chief Financial Officer Robb A. LeMasters has stepped down, with the filing stating the decision is not related to any financial or accounting issue or disagreement with the company. Vice President, Finance and Chief Accounting Officer Michael T. Fitzgerald was appointed interim CFO effective May 12, 2025, and Mr. LeMasters will remain as Special Advisor to the CEO through March 2, 2026.
Robb A. LeMasters stepped down as executive vice president and CFO; the transition agreement was entered into May 11, 2025.
Mr. LeMasters will receive salary of $494,795 through March 2, 2026, plus a cash retention bonus of $105,205, and will not take part in the 2025 annual incentive plan or the 2026 incentive plans.
Michael T. Fitzgerald, 41, was named interim senior vice president and CFO effective May 12, 2025, with a 27% base salary increase and a 55% target non-equity incentive.
Chewy said Chief Financial Officer David Reeder will leave the company to become a chief executive officer in the semiconductor industry, with his departure date still to be determined. The company also reaffirmed its first quarter fiscal 2025 guidance, and CEO Sumit Singh said the long-term plan remains intact.
Reeder notified Chewy on May 7, 2025 that he will resign as CFO and principal financial officer.
Reeder will remain CFO through the company's next earnings announcement in June, and the company is searching for a successor.
Chewy reaffirmed its previously announced first quarter fiscal 2025 guidance in a May 12, 2025 press release.
The filing states Reeder's resignation was not the result of any disagreement with the company on operations, policies, financial disclosures, or accounting matters.
Fortrea reported first-quarter 2025 revenue of $651.3 million, down from $662.1 million a year earlier, and a GAAP net loss of $562.9 million that includes a non-cash goodwill impairment charge of $488.8 million. Adjusted EBITDA rose to $30.3 million from $27.1 million, and the company reiterated its full-year 2025 guidance. Chairman and CEO Thomas Pike will step down on May 13, 2025, and Lead Independent Director Peter M. Neupert will serve as interim CEO and Board Chair.
Revenue was $651.3 million in the quarter, compared with $662.1 million in the first quarter of 2024.
GAAP net loss was $562.9 million, or $6.25 per diluted share, including the $488.8 million goodwill impairment; adjusted EPS was $0.02 versus $(0.05) a year earlier.
Adjusted EBITDA was $30.3 million, compared with $27.1 million in the first quarter of 2024.
Full-year 2025 guidance was reiterated at revenue of $2.45 billion to $2.55 billion and adjusted EBITDA of $170 million to $200 million; Peter M. Neupert becomes interim CEO on May 13, 2025.
Sally Beauty reported fiscal second-quarter results for the period ended March 31, 2025, with net sales down 2.8% to $883.1 million and comparable sales down 1.3%. GAAP diluted EPS rose to $0.38 from $0.27, and adjusted diluted EPS rose 20% to $0.42, while the company updated its full-year fiscal 2025 guidance and extended its share repurchase program to September 30, 2029.
Net sales of $883.1 million, down 2.8%; comparable sales down 1.3%, which the company attributed to weather, an unusually harsh flu season and macro uncertainty
GAAP diluted EPS of $0.38 versus $0.27 a year earlier; adjusted diluted EPS of $0.42 versus $0.35, a 20% increase
Full-year fiscal 2025 guidance: comparable sales flat to down 1%; adjusted operating margin of 8.0% to 8.5%
Board approved extending the share repurchase program to September 30, 2029, with $501.1 million remaining under the authorization
IDACORP entered into an underwriting agreement on May 8, 2025 for an underwritten public offering of 4,504,505 shares of common stock, with an additional 675,675 shares added when underwriters exercised their option in full on May 9, 2025. The shares were borrowed from third parties and sold through forward sale agreements, with settlement at IDACORP's discretion by November 9, 2026, so the company's share count and earnings per share could rise if it chooses to physically settle.
Offering totals 4,504,505 shares, plus 675,675 option shares exercised in full on May 9, 2025.
Initial forward sale price is $107.67 per share, subject to adjustments for an overnight bank funding rate less a spread and expected dividends.
IDACORP expects no dilutive effect on earnings per share unless the average market price exceeds the adjusted forward sale price.
Settlement must occur by November 9, 2026, and IDACORP may choose physical, cash, or net share settlement.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.